Novel Prostate Cancer Cell Lines to Address Prostate Cancer Disparity in Black Men

这项工作是基于这样一个假设，即为了充分利用细胞系药物的好处 筛选，一个具有代表性的细胞系小组，概括了不同类型的前列腺癌(PCa) 而血统差异的贡献是必要的。前列腺癌是导致癌症的主要原因。 全球男性死亡率。目前在患者诊断和治疗方面的进步导致了 前列腺癌发病率和死亡率下降。然而，非洲人的情况并非如此。 血统(MAA)来自非洲和加勒比地区，那里的PCA发病率和死亡率都是 呈上升趋势。前列腺癌细胞系被用来了解前列腺癌的生物学特性，并促进 主成分分析治疗的进展。然而，超过97%的前列腺癌细胞株很容易 提供给研究人员的是来自欧洲血统(MEA)的男性。继续存在着有限的 MAA和MEA的PCA材料表示，几乎没有细胞 可供选择的型号来自MAA。这使得很难评估潜在的疗效。 在MAA和MEA中的治疗，导致了健康差距的问题。要解决这个问题 问题，这个项目将首先开发和表征概括最多的细胞系 MAA中与PCA相关的普遍分子异常(目标1)。其次，它将 在小说中对比筛选化疗药物和牙买加天然铅分子 MAA-PCa细胞系标准使用来源于MEA的PCa细胞系(目标2)。

This work is based on the hypothesis that to fully exploit the benefit of cell line-based drug screening, a representative cell line panel recapitulating the varied types of prostate cancer (PCa) and the contribution of differences in ancestry is necessary. PCa is the leading cause of cancer mortality in men worldwide. Current advances in patient diagnoses and therapy have led to a decline in PCa incidence and mortality rates. However, this is not the case for men of African ancestry (MAA) from Africa and the Caribbean where both PCa incidence and mortality rates are on the rise. PCa cell lines are used to understand the biology of PCa and to advance the development of PCa theranostics. However, more than 97% of the PCa cell lines that are readily available to researchers are from men of European ancestry (MEA). There continues to be limited representation of PCa materials from MAA when compared to MEA, and there are almost no cell models available derived from MAA. This makes it difficult to assess the efficacy of potential treatments in MAA versus MEA, contributing to a problem in health disparities. To address this problem, this project will first develop and characterize cell lines that recapitulate the most prevalent molecular abnormalities associated with PCa in MAA (Aim 1). Second, it will comparatively screen chemotherapy drugs and Jamaican natural lead molecules on the novel MAA PCa cell lines to standardly employed PCa cell lines derived from MEA (Aim 2).